NuPathe Licenses Novel Drug Delivery Technology from University of Pennsylvania to Support Development of Therapies to Treat Neurologic and Psychiatric Disorders

August 16, 2006 09:01 AM Eastern Daylight Time

BIOWIRE2K

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Aug. 16, 2006--

Technology Could Lead to New Single-Dose Therapies for Patients with Conditions Including Parkinson's Disease and Schizophrenia

> "As an established center for innovative medical research, the University of Pennsylvania is pleased to license technology to NuPathe to help to take this important discovery to the next stage and bring the advantages of the LAD(TM) drug delivery technology to patients around the world who need it"

NuPathe Inc., a specialty pharmaceutical company focusing on innovative therapeutic products in the area of neuroscience, announced today that it has entered into an exclusive worldwide license agreement with the University of Pennsylvania for the LAD(TM) long acting delivery technology.

The LAD(TM) long acting delivery technology is designed to improve control, consistency and convenience in drug delivery by making it possible to treat patients with a single dose of a therapy over a one to three month period. LAD(TM) consists of a small biodegradable polymer matrix, no bigger than a grain of rice. Using this technology, a drug can be administered via injection to be positioned just below the skin, where it slowly releases the drug to patients and degrades over a defined period of time.

"The development of drug delivery options that make both current and new drug therapies more effective is a core focus of NuPathe's business platform. This important advance in drug delivery technology from the University of Pennsylvania shows the clear potential to revolutionize the way that drugs to treat many serious neurological illnesses are delivered," said Jane Hollingsworth, CEO of NuPathe.

LAD(TM) was developed by Dr. Steven Siegel and his colleagues at the University of Pennsylvania. In early stage research, Dr. Siegel demonstrated that LAD(TM) can successfully deliver several classes of neuropsychiatric drugs for defined time periods. By reducing dose frequency and helping patients to maintain a more consistent dose level during treatment, medications developed based on the LAD (TM) technology could lead to improved efficacy and better compliance.

"By addressing critical issues in drug delivery, the LAD(TM) technology could significantly improve both the convenience and the efficacy of treatments for many serious neurological disorders. I am especially pleased that the team at NuPathe, with outstanding experience in product development involving innovative delivery technologies, will be working to advance this platform in the years ahead," said Dr. Siegel.

NuPathe is currently advancing two product candidates based on the LAD(TM) delivery technology. NP201 is a dopamine agonist in development as a potential treatment for Parkinson's disease. By delivering drug with greater consistency in a single-dose option for patients, NP201 has the potential to reduce complications associated with Parkinson's treatments such as abnormal movements.

NP202 is in development as an antipsychotic for the treatment of schizophrenia. Using the LAD(TM) technology, NP202 is being designed to deliver drug in a controlled, sustained manner over a three month period. This may improve efficacy and reduce the risk of relapse in patients who do not comply with the dosing schedule of their current antipsychotic medications.

"As an established center for innovative medical research, the University of Pennsylvania is pleased to license technology to NuPathe to help to take this important discovery to the next stage and bring the advantages of the LAD(TM) drug delivery technology to patients around the world who need it," said John Zawad, Managing Director, Center for Technology Transfer at the University of Pennsylvania.

About NuPathe: NuPathe is a specialty pharmaceutical company developing innovative products for the treatment of neurological and psychiatric diseases. NuPathe is currently developing products to address acute migraine, Parkinson's disease and schizophrenia.

NuPathe's lead product, NP101, is in development as a potential treatment for migraine with administration via a dermal patch. Using NuPathe's SmartRelief(TM) transdermal patch technology, NP101 is able to rapidly deliver migraine medication through the skin while maintaining an appropriate therapeutic concentration over an extended period of time. The ability to deliver migraine medication through a fast and long-acting patch may provide a valuable alternative for migraine patients suffering from nausea, vomiting or frequent migraine recurrence. NP101 is currently in Phase I clinical development and is anticipated to enter Phase III clinical testing in early 2007.

More information about NuPathe is available at www.nupathe.com.

Contacts

NuPathe Inc.
Corporate Contact:
Jane Hollingsworth, 484-567-0130
or
Media Contact:
Berry & Company
John Payne, 212-253-8881